11/20
09:01 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
11/18
11:38 am
mdgl
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade [Yahoo! Finance]
11/10
09:37 am
mdgl
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More [Yahoo! Finance]
Low
Report
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More [Yahoo! Finance]
11/7
01:42 pm
mdgl
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy [Yahoo! Finance]
Low
Report
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy [Yahoo! Finance]
11/6
08:00 am
mdgl
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
Low
Report
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
11/5
11:19 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target raised by analysts at B. Riley from $194.00 to $236.00. They now have a "neutral" rating on the stock.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target raised by analysts at B. Riley from $194.00 to $236.00. They now have a "neutral" rating on the stock.
11/2
10:36 am
mdgl
Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts [Yahoo! Finance]
Medium
Report
Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts [Yahoo! Finance]
11/1
02:51 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target raised by analysts at UBS Group AG from $411.00 to $441.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target raised by analysts at UBS Group AG from $411.00 to $441.00. They now have a "buy" rating on the stock.
11/1
10:29 am
mdgl
Novo Nordisk Says Wegovy Improved Patients' Liver Disease [Yahoo! Finance]
Medium
Report
Novo Nordisk Says Wegovy Improved Patients' Liver Disease [Yahoo! Finance]
10/31
07:00 am
mdgl
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
High
Report
Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
10/30
08:00 am
mdgl
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
Low
Report
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
10/24
12:15 pm
mdgl
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings [Seeking Alpha]
Low
Report
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings [Seeking Alpha]
10/23
08:34 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $375.00 to $350.00. They now have an "outperform" rating on the stock.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $375.00 to $350.00. They now have an "outperform" rating on the stock.
10/22
08:32 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $390.00 price target on the stock.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $390.00 price target on the stock.
10/22
07:42 am
mdgl
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug [Yahoo! Finance]
10/21
08:00 am
mdgl
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
Low
Report
Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
10/18
08:00 am
mdgl
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
Low
Report
Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
10/12
02:05 am
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
10/11
01:49 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald.
10/8
07:07 am
mdgl
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status [Yahoo! Finance]
Low
Report
Boehringer kickstarts two Phase III trials as MASH therapy wins breakthrough status [Yahoo! Finance]
10/2
11:05 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
10/2
08:00 am
mdgl
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
Low
Report
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
10/1
08:00 am
mdgl
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
Medium
Report
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
9/30
08:00 am
mdgl
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
Low
Report
Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
9/20
11:31 pm
mdgl
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) was upgraded by analysts at StockNews.com to a "sell" rating.